BI/Lilly submit NDA for SGLT2 empagliflozin
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and Lilly on 25 March revealed they "recently" submitted a new drug application (NDA) to the US FDA for the companies' investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin as a treatment for Type II diabetes in adults.